Tailoring antiplatelet therapy in older patients with coronary artery disease
Platelets. 2023 Dec;34(1):2285446. doi: 10.1080/09537104.2023.2285446. Epub 2023 Dec 5.ABSTRACTThe older population represents a unique subset of patients due to a higher rate of comorbidities and risk factors, which can lead to a higher rate of ischemic and bleeding events. As a result, older adults are mainly underrepresented or excluded from randomized trials. Although the advancement in the percutaneous coronary intervention field with the development of new technologies, techniques, and potent antiplatelet therapy led to a reduction of ischemic risk, there is still a concern regarding bleeding hazards. Apart from the ...
Source: Platelets - December 5, 2023 Category: Hematology Authors: Mila Kovacevic Graziella Pompei Vijay Kunadian Source Type: research

Optimizing the therapeutic window of sirolimus by monitoring blood concentration for the treatment of immune thrombocytopenia
Platelets. 2023 Dec;34(1):2277831. doi: 10.1080/09537104.2023.2277831. Epub 2023 Nov 20.ABSTRACTPrevious studies have demonstrated that sirolimus (SRL) is an effective agent for the treatment of refractory/relapsed (R/R) ITP. However, the therapeutic window of sirolimus in the treatment of ITP has not been established. As the toxicity of sirolimus increases with higher blood concentrations, it is crucial to determine the optimal therapeutic concentration of SRL for the treatment of ITP. Thus, in this study, we used a retrospective cohort of ITP patients treated with sirolimus to propose the therapeutic dosage window for si...
Source: Platelets - December 5, 2023 Category: Hematology Authors: Yun Zhang Yao Quan Dan Wang Kaniel Cassady Wenhang Zou Jingkang Xiong Han Yao Xiaojuan Deng Ping Wang Shijie Yang Xi Zhang Yimei Feng Source Type: research

Tailoring antiplatelet therapy in older patients with coronary artery disease
Platelets. 2023 Dec;34(1):2285446. doi: 10.1080/09537104.2023.2285446. Epub 2023 Dec 5.ABSTRACTThe older population represents a unique subset of patients due to a higher rate of comorbidities and risk factors, which can lead to a higher rate of ischemic and bleeding events. As a result, older adults are mainly underrepresented or excluded from randomized trials. Although the advancement in the percutaneous coronary intervention field with the development of new technologies, techniques, and potent antiplatelet therapy led to a reduction of ischemic risk, there is still a concern regarding bleeding hazards. Apart from the ...
Source: Platelets - December 5, 2023 Category: Hematology Authors: Mila Kovacevic Graziella Pompei Vijay Kunadian Source Type: research

Optimizing the therapeutic window of sirolimus by monitoring blood concentration for the treatment of immune thrombocytopenia
Platelets. 2023 Dec;34(1):2277831. doi: 10.1080/09537104.2023.2277831. Epub 2023 Nov 20.ABSTRACTPrevious studies have demonstrated that sirolimus (SRL) is an effective agent for the treatment of refractory/relapsed (R/R) ITP. However, the therapeutic window of sirolimus in the treatment of ITP has not been established. As the toxicity of sirolimus increases with higher blood concentrations, it is crucial to determine the optimal therapeutic concentration of SRL for the treatment of ITP. Thus, in this study, we used a retrospective cohort of ITP patients treated with sirolimus to propose the therapeutic dosage window for si...
Source: Platelets - December 5, 2023 Category: Hematology Authors: Yun Zhang Yao Quan Dan Wang Kaniel Cassady Wenhang Zou Jingkang Xiong Han Yao Xiaojuan Deng Ping Wang Shijie Yang Xi Zhang Yimei Feng Source Type: research

Tailoring antiplatelet therapy in older patients with coronary artery disease
Platelets. 2023 Dec;34(1):2285446. doi: 10.1080/09537104.2023.2285446. Epub 2023 Dec 5.ABSTRACTThe older population represents a unique subset of patients due to a higher rate of comorbidities and risk factors, which can lead to a higher rate of ischemic and bleeding events. As a result, older adults are mainly underrepresented or excluded from randomized trials. Although the advancement in the percutaneous coronary intervention field with the development of new technologies, techniques, and potent antiplatelet therapy led to a reduction of ischemic risk, there is still a concern regarding bleeding hazards. Apart from the ...
Source: Platelets - December 5, 2023 Category: Hematology Authors: Mila Kovacevic Graziella Pompei Vijay Kunadian Source Type: research

Optimizing the therapeutic window of sirolimus by monitoring blood concentration for the treatment of immune thrombocytopenia
Platelets. 2023 Dec;34(1):2277831. doi: 10.1080/09537104.2023.2277831. Epub 2023 Nov 20.ABSTRACTPrevious studies have demonstrated that sirolimus (SRL) is an effective agent for the treatment of refractory/relapsed (R/R) ITP. However, the therapeutic window of sirolimus in the treatment of ITP has not been established. As the toxicity of sirolimus increases with higher blood concentrations, it is crucial to determine the optimal therapeutic concentration of SRL for the treatment of ITP. Thus, in this study, we used a retrospective cohort of ITP patients treated with sirolimus to propose the therapeutic dosage window for si...
Source: Platelets - December 5, 2023 Category: Hematology Authors: Yun Zhang Yao Quan Dan Wang Kaniel Cassady Wenhang Zou Jingkang Xiong Han Yao Xiaojuan Deng Ping Wang Shijie Yang Xi Zhang Yimei Feng Source Type: research

Tailoring antiplatelet therapy in older patients with coronary artery disease
Platelets. 2023 Dec;34(1):2285446. doi: 10.1080/09537104.2023.2285446. Epub 2023 Dec 5.ABSTRACTThe older population represents a unique subset of patients due to a higher rate of comorbidities and risk factors, which can lead to a higher rate of ischemic and bleeding events. As a result, older adults are mainly underrepresented or excluded from randomized trials. Although the advancement in the percutaneous coronary intervention field with the development of new technologies, techniques, and potent antiplatelet therapy led to a reduction of ischemic risk, there is still a concern regarding bleeding hazards. Apart from the ...
Source: Platelets - December 5, 2023 Category: Hematology Authors: Mila Kovacevic Graziella Pompei Vijay Kunadian Source Type: research

Optimizing the therapeutic window of sirolimus by monitoring blood concentration for the treatment of immune thrombocytopenia
Platelets. 2023 Dec;34(1):2277831. doi: 10.1080/09537104.2023.2277831. Epub 2023 Nov 20.ABSTRACTPrevious studies have demonstrated that sirolimus (SRL) is an effective agent for the treatment of refractory/relapsed (R/R) ITP. However, the therapeutic window of sirolimus in the treatment of ITP has not been established. As the toxicity of sirolimus increases with higher blood concentrations, it is crucial to determine the optimal therapeutic concentration of SRL for the treatment of ITP. Thus, in this study, we used a retrospective cohort of ITP patients treated with sirolimus to propose the therapeutic dosage window for si...
Source: Platelets - December 5, 2023 Category: Hematology Authors: Yun Zhang Yao Quan Dan Wang Kaniel Cassady Wenhang Zou Jingkang Xiong Han Yao Xiaojuan Deng Ping Wang Shijie Yang Xi Zhang Yimei Feng Source Type: research

Tailoring antiplatelet therapy in older patients with coronary artery disease
Platelets. 2023 Dec;34(1):2285446. doi: 10.1080/09537104.2023.2285446. Epub 2023 Dec 5.ABSTRACTThe older population represents a unique subset of patients due to a higher rate of comorbidities and risk factors, which can lead to a higher rate of ischemic and bleeding events. As a result, older adults are mainly underrepresented or excluded from randomized trials. Although the advancement in the percutaneous coronary intervention field with the development of new technologies, techniques, and potent antiplatelet therapy led to a reduction of ischemic risk, there is still a concern regarding bleeding hazards. Apart from the ...
Source: Platelets - December 5, 2023 Category: Hematology Authors: Mila Kovacevic Graziella Pompei Vijay Kunadian Source Type: research

Optimizing the therapeutic window of sirolimus by monitoring blood concentration for the treatment of immune thrombocytopenia
Platelets. 2023 Dec;34(1):2277831. doi: 10.1080/09537104.2023.2277831. Epub 2023 Nov 20.ABSTRACTPrevious studies have demonstrated that sirolimus (SRL) is an effective agent for the treatment of refractory/relapsed (R/R) ITP. However, the therapeutic window of sirolimus in the treatment of ITP has not been established. As the toxicity of sirolimus increases with higher blood concentrations, it is crucial to determine the optimal therapeutic concentration of SRL for the treatment of ITP. Thus, in this study, we used a retrospective cohort of ITP patients treated with sirolimus to propose the therapeutic dosage window for si...
Source: Platelets - December 5, 2023 Category: Hematology Authors: Yun Zhang Yao Quan Dan Wang Kaniel Cassady Wenhang Zou Jingkang Xiong Han Yao Xiaojuan Deng Ping Wang Shijie Yang Xi Zhang Yimei Feng Source Type: research

Tailoring antiplatelet therapy in older patients with coronary artery disease
Platelets. 2023 Dec;34(1):2285446. doi: 10.1080/09537104.2023.2285446. Epub 2023 Dec 5.ABSTRACTThe older population represents a unique subset of patients due to a higher rate of comorbidities and risk factors, which can lead to a higher rate of ischemic and bleeding events. As a result, older adults are mainly underrepresented or excluded from randomized trials. Although the advancement in the percutaneous coronary intervention field with the development of new technologies, techniques, and potent antiplatelet therapy led to a reduction of ischemic risk, there is still a concern regarding bleeding hazards. Apart from the ...
Source: Platelets - December 5, 2023 Category: Hematology Authors: Mila Kovacevic Graziella Pompei Vijay Kunadian Source Type: research

Optimizing the therapeutic window of sirolimus by monitoring blood concentration for the treatment of immune thrombocytopenia
Platelets. 2023 Dec;34(1):2277831. doi: 10.1080/09537104.2023.2277831. Epub 2023 Nov 20.ABSTRACTPrevious studies have demonstrated that sirolimus (SRL) is an effective agent for the treatment of refractory/relapsed (R/R) ITP. However, the therapeutic window of sirolimus in the treatment of ITP has not been established. As the toxicity of sirolimus increases with higher blood concentrations, it is crucial to determine the optimal therapeutic concentration of SRL for the treatment of ITP. Thus, in this study, we used a retrospective cohort of ITP patients treated with sirolimus to propose the therapeutic dosage window for si...
Source: Platelets - December 5, 2023 Category: Hematology Authors: Yun Zhang Yao Quan Dan Wang Kaniel Cassady Wenhang Zou Jingkang Xiong Han Yao Xiaojuan Deng Ping Wang Shijie Yang Xi Zhang Yimei Feng Source Type: research

Tailoring antiplatelet therapy in older patients with coronary artery disease
Platelets. 2023 Dec;34(1):2285446. doi: 10.1080/09537104.2023.2285446. Epub 2023 Dec 5.ABSTRACTThe older population represents a unique subset of patients due to a higher rate of comorbidities and risk factors, which can lead to a higher rate of ischemic and bleeding events. As a result, older adults are mainly underrepresented or excluded from randomized trials. Although the advancement in the percutaneous coronary intervention field with the development of new technologies, techniques, and potent antiplatelet therapy led to a reduction of ischemic risk, there is still a concern regarding bleeding hazards. Apart from the ...
Source: Platelets - December 5, 2023 Category: Hematology Authors: Mila Kovacevic Graziella Pompei Vijay Kunadian Source Type: research

Tissue inhibitors of metalloproteinases (TIMPs) modulate platelet ADAM10 activity
Platelets. 2023 Dec;34(1):2288213. doi: 10.1080/09537104.2023.2288213. Epub 2023 Nov 30.ABSTRACTPlatelet-specific collagen receptor glycoprotein (GP)VI is stable on the surface of circulating platelets but undergoes ectodomain cleavage on activated platelets. Activation-dependent GPVI metalloproteolysis is primarily mediated by A Disintegrin And Metalloproteinase (ADAM) 10. Regulation of platelet ADAMs activity is not well-defined however Tissue Inhibitors of Metalloproteinases (TIMPs) may play a role. As levels of TIMPs on platelets and the control of ADAMs-mediated shedding by TIMPs has not been evaluated, we quantified ...
Source: Platelets - November 30, 2023 Category: Hematology Authors: Christine Shu Mei Lee Amandeep Kaur Samantha J Montague Sarah M Hicks Robert K Andrews Elizabeth E Gardiner Source Type: research

Performance evaluation of PLT-H (hybrid-channel platelet) under various interferences and application studies for platelet transfusion decisions
In this study, we aimed to evaluate the accuracy of this technique in various situations and its reliability in platelet transfusion decision-making. A total of 378 venous blood samples were tested. Using the immunological PLT counting method recommended by the International Council for Standardization in Hematology as the reference method (PLT-IRM), Passing-Bablok regression and Bland-Altman analysis were performed on the PLT-H results. The anti-interference performance of PLT-H under different interference levels was explored using intergroup comparisons, and confusion matrices were analyzed at various transfusion cutoff...
Source: Platelets - November 30, 2023 Category: Hematology Authors: Qi Cai Han Lin Ping Guo Source Type: research